Press Kit
Press & Partner Resources
Downloadable assets for journalists, partners, and investors. Whitepaper is generated live from current data — always reflects the latest metrics.
Whitepaper
MolForge Whitepaper (4-page PDF)
One-page summary + Technology + Validation & Evidence Gates + Target Portfolio + Contact. Generated client-side from live data on this site — numbers always current.
- • Page 1: Executive summary + key metrics
- • Page 2: Technology stack (MolForge-Gen, ROBOGATE, CP, Boltz-2)
- • Page 3: Three Evidence Gates with current status
- • Page 4: Target portfolio (TYK2, TNIK, CDK4/6) + contact
Live Numbers (Snapshot)
Fact Sheet
Quick Reference
Company
AgentAI Labs Co., Ltd.
Business Reg.
117-86-03600
Headquarters
Gangnam-gu, Seoul, Korea
CEO
Heonjeong Cho — hj@molforgeai.com
CTO
Jewoo Yom — jwyom@molforgeai.com
Patent
KIPO 10-2026-0057732 (ROBOGATE method)
Targets
TYK2, TNIK, CDK4, CDK6, EGFR
Indications
Autoimmune, Oncology, Obesity, IPF
Stage
Gate A passed; Gate B (CRO) in progress
Partnership
NDA-based evaluation; Series A-B biotech / pharma R&D
Web
https://www.molforgeai.com
Press inquiries
contact@molforgeai.com
Company Boilerplate
MolForge is the AI drug discovery platform built by AgentAI Labs Co., Ltd. Built on the proprietary MolForge-Gen molecular transformer (25.4M parameters, trained on 1.6M drug-like molecules), MolForge maps the failure boundary of chemical space — identifying exactly which structural modifications cause ADMET failures before any synthesis. The platform integrates Boltz-2 structure prediction, ADMET-AI property scoring, and proprietary Conformal Prediction uncertainty quantification into a fully automated 24/7 pipeline. As of April 2026, 68,530 ADMET-validated compounds have been generated across TYK2 (autoimmune), CDK4/6 (oncology), and TNIK (oncology + obesity, first-in-class opportunity).